News and Announcements
Revenue Generating SaaS FinTech with 11% Day-on-Day In-App Activity Growth | Selected for Barclays and Techstars Accelerator Programme
- Published October 14, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
“In the upcoming years, HiStreet will become a tax product that will be legally enforced and freely advertised by the UK government.
Our product will be in the hands of 3.5 million sole traders in the UK in 18 months, and these individuals will have easy access to our HiStreet tax software. HMRC will also express support by advertising our solution on the UK government website.
As Crowdcube has offered to run a campaign for us with a £250K investment estimate from their customer base, we plan to wrap up this raise as quickly as possible.”
Neil Patti-Dhanjal, Co-founder, HiStreet
Executive Summary
HiStreet is a SaaS FinTech with an invoicing and tax app for sole traders. It has a network of over 3.5 million traders in the UK aiming to meet the government’s requirement to use a digital tax solution to submit their income and expenses four times per year – a simpler solution than other tax apps that target larger businesses.
Investment Highlights
- The app’s processed invoices have been generating revenue and growing by 11% every day – two months from its product launch.
- Barclays Eagle Labs accelerator and Techstars programme has selected HiStreet as the featured company.
- Crowdcube is campaigning HiStreet with a £250K investment estimate from their customer base.
- The HiStreet App has received 5-star reviews in the Apple App Store
Investment Offering
HiStreet is raising £500K in exchange for equity. The company is in late-stage discussions with several of Europe’s leading VCs.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
